Abstract
Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Antiviral Agents* / adverse effects
-
Antiviral Agents* / therapeutic use
-
Cross Reactions
-
Drug Substitution
-
Eosinophilia / chemically induced*
-
Exanthema / chemically induced*
-
Genotype
-
Hepacivirus / drug effects
-
Hepacivirus / physiology
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Male
-
Middle Aged
-
Oligopeptides / adverse effects*
-
Proline / analogs & derivatives*
-
Proline / therapeutic use
-
RNA, Viral / genetics
-
Viral Load
Substances
-
Antiviral Agents
-
Oligopeptides
-
RNA, Viral
-
telaprevir
-
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
-
Proline